Please assess the completion status of the following clinical trial:

Trial Title: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age ≥18 and \<75 years~* Diagnosis of Esophageal cancer or Esophagogastric junction cancer.~* Previously received treatment for advanced or metastatic disease.~* Measurable disease according to RECIST v1.1.~* HLA-A\*02 positive~* Tumor shows MAGE-A4 expression confirmed by central laboratory.~* ECOG Performance Status of 0 or1.~* Left ventricular ejection fraction (LVEF) ≥50%.~Note: other protocol defined Inclusion criteria may apply~Key exclusion criteria~1. Positive for any HLA-A\*02 allele other than: one of the inclusion alleles~2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study~3. Active autoimmune or immune mediated disease~4. Leptomeningeal disease, carcinomatous meningitis or symptomatic CNS metastases~5. Other prior malignancy that is not considered by the Investigator to be in complete remission. Clinically significant cardiovascular disease~6. Uncontrolled intercurrent illness~7. Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus~8. Pregnant or breastfeeding~Note: other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Autologous genetically modified ADP-A2M4CD8 cells (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).